Mucosal Immunity: MALT, M Cells, and How Secretory IgA Reaches the Surface

The body's mucosal surfaces (the lining of the gut, airways, and urogenital tract) add up to a vast area, far larger than the skin, and they are thin by necessity: they have to absorb nutrients, exchange gases, and pass fluids. That thinness is also a vulnerability, because it is exactly where most pathogens first try to enter.

Mucosal immunity is the specialized branch of the immune system that guards these surfaces. It is distinct enough in its organization that it is often treated as an immune system of its own, running somewhat separately from the systemic immunity of the blood and spleen.

This article covers how that system is built and how it works: the lymphoid tissue that organizes it, the way it samples antigen, and the route by which its main antibody reaches the surface. The molecular structure of secretory IgA is covered separately in the article on IgA; here the focus is the tissue and the traffic.

Mucosa-Associated Lymphoid Tissue (MALT)

The mucosal immune system is organized around mucosa-associated lymphoid tissue (MALT): collections of lymphoid tissue that sit just beneath mucosal surfaces rather than in the encapsulated lymph nodes and spleen of the systemic system. MALT is named by location:

• GALT (gut-associated lymphoid tissue): the largest, including Peyer's patches in the small intestine, the appendix, and isolated lymphoid follicles.
• BALT (bronchus-associated lymphoid tissue): in the airways.
• NALT (nasopharynx-associated lymphoid tissue): including the tonsils and adenoids.

Together, MALT contains more lymphocytes than all the systemic lymphoid organs combined, which reflects how much of the body's immune effort is spent defending mucosal surfaces.

Inductive Sites and Effector Sites

The single most useful idea for understanding mucosal immunity is that it splits its work across two kinds of location, and they are not the same place.

Inductive sites are where a mucosal immune response is started. These are the organized MALT structures such as Peyer's patches. Here, antigen is sampled from the lumen, presented to T and B cells, and a response is triggered. Think of the inductive site as the training ground.

Effector sites are where the response is carried out. These are the diffuse tissues of the mucosa itself: the lamina propria and the epithelium, spread out along the gut wall and airways. Here, the plasma cells secrete antibody and the surface is actually defended. Think of the effector site as the front line.

The reason this split matters is that the two are connected by cell traffic. A B cell activated in a Peyer's patch does not stay there. It leaves, travels through lymph and blood, and homes back to the effector tissue to do its job. That journey is the heart of how mucosal immunity works, and it is described below.

M Cells: Sampling the Antigen

A mucosal surface faces a problem: the epithelium is a sealed barrier meant to keep the lumen out, but the immune system underneath needs to see what is in the lumen in order to respond to it. The solution is a specialized epithelial cell called the M cell (microfold cell), found in the epithelium overlying Peyer's patches and other inductive sites.

M cells do not digest or absorb. Their job is transport: they take up antigens and whole microorganisms from the lumen by endocytosis and hand them across to the immune cells waiting in a pocket on the other side. An M cell has a distinctive shape, with a deep basolateral pocket that holds dendritic cells, macrophages, and lymphocytes right up against the point of delivery. The antigen is sampled, passed to a dendritic cell, and presented, all within the inductive site.

This sampling route is efficient, but it is also a vulnerability: several pathogens, including Salmonella Typhi and poliovirus, exploit M cells as their way across the epithelium. The same door that lets the immune system look out lets some invaders in.

The IgA Plasma Cell Journey (Homing)

Once a B cell is activated in an inductive site such as a Peyer's patch, class-switches to IgA, and becomes a plasmablast, it follows a defined path:

1. It leaves the Peyer's patch and drains into the mesenteric lymph nodes.
2. From there it enters the thoracic duct and joins the bloodstream.
3. It then homes back to mucosal effector tissue, guided by adhesion molecules and chemokine receptors (the gut-homing signal MAdCAM-1 recognized by the integrin α4β7 is the classic example) that direct it to the lamina propria.
4. In the lamina propria it matures into a plasma cell and secretes dimeric IgA.

The consequence of this homing is subtle but important: because the activated cells circulate before settling, immunity induced at one mucosal site can appear at others. A response started in the gut can seed IgA-secreting cells in the respiratory or mammary mucosa. This linkage is called the common mucosal immune system, and it is why, for example, a mother's gut exposure translates into protective IgA in her breast milk.

The pIgR Pathway: Getting IgA to the Surface

Secreting IgA into the lamina propria is not enough. The antibody has to cross the epithelial barrier to reach the lumen where the pathogens are. It cannot simply diffuse across a sealed epithelium, so it is actively carried across by a dedicated transport receptor.

The dimeric IgA secreted by the plasma cell binds the polymeric immunoglobulin receptor (pIgR) on the basolateral (blood-facing) surface of the epithelial cell. The receptor carries the IgA through the cell by transcytosis to the apical (lumen-facing) surface. There the receptor is cleaved, and a piece of it, the secretory component, stays attached to the IgA as it is released into the lumen as secretory IgA (sIgA). The secretory component is not just leftover packaging: it protects the antibody from being digested by the proteases abundant at mucosal surfaces.

The molecular anatomy of the finished sIgA molecule (the dimer, the J chain, and the secretory component) is covered in the IgA article. What matters here is the route: basolateral binding, transcytosis, apical release with the secretory component attached.

Bacteria That Fight Back: IgA Protease

Because secretory IgA is the main obstacle to colonizing a mucosal surface, several important pathogens have evolved a way around it. They secrete an enzyme called IgA protease that cleaves the antibody in its hinge region, splitting off the antigen-binding arms and leaving the pathogen free to attach to the epithelium.

The classic producers are the bacteria that colonize the respiratory and genital mucosa: Haemophilus influenzae, Streptococcus pneumoniae, Neisseria gonorrhoeae, and Neisseria meningitidis. Notably, the enzyme is specific for IgA1 (the subclass with the longer, more exposed hinge) and does not cleave IgA2, which is one reason IgA2 makes up a larger share of antibody at some mucosal sites than it does in serum. IgA protease is treated as a virulence factor, a major contributor in bacterial pathogenesis.

Why Mucosal Vaccines Are Different

Understanding inductive sites explains a practical clinical point. A response has to be induced at a mucosal surface to generate strong mucosal (sIgA) immunity. An injected vaccine, delivered into muscle, is very good at raising systemic IgG but poor at raising mucosal sIgA, because it never engages the mucosal inductive sites.

This is why some vaccines are given by the mucosal route. The oral polio vaccine and the live attenuated intranasal influenza vaccine engage GALT and NALT directly, producing sIgA at the surface where the pathogen enters. It is also part of why several respiratory-virus vaccines given by injection protect well against severe disease (systemic IgG) but less well against initial infection and transmission at the mucosa (where sIgA would matter most).

How to Remember

Inductive site = where it starts; effector site = where it fights. Peyer's patch trains the cell; the lamina propria is the front line. The cell travels from one to the other. If you hold that split, the whole system falls into place.

M cell = the window in the wall. The epithelium is a sealed wall; the M cell is the sampling window that lets the immune system see the lumen. Same window some pathogens climb through.

The IgA cell's road trip: patch → node → duct → blood → back home. The plasma cell is activated in the Peyer's patch, circulates, and homes back to mucosa. Because it circulates, immunity at one surface shows up at others (the common mucosal immune system).

pIgR: in through the back, out through the front. Dimeric IgA binds pIgR on the basolateral (back) surface, rides through the cell, and is released apically (front) as secretory IgA, keeping the secretory component as armor.

Who cuts IgA? "HiSpNg" (His-Ping): Haemophilus influenzae, Streptococcus pneumoniae, Neisseria. The mucosal colonizers that produce IgA protease are the same organisms that need to get past sIgA to settle in the respiratory and genital tract. They cut IgA1, not IgA2.

Key Exam Facts

Where Students Get Confused

"MALT is one organ." No. MALT is a category of lymphoid tissue found at many sites (GALT in the gut, BALT in the airways, NALT in the nasopharynx). It is defined by being under a mucosal surface, not by being one structure.

"Antigen is sampled and antibody is secreted in the same place." No, and this is the key point of the whole topic. The response is induced at inductive sites (Peyer's patches) but carried out at effector sites (the lamina propria). The activated cell physically travels from one to the other.

"The M cell is part of the immune system." The M cell is an epithelial cell, not an immune cell. It is a transporter: it samples antigen and hands it to the immune cells beneath. It does not present antigen itself in the way a dendritic cell does.

"Secretory IgA just diffuses out onto the surface." No. It is actively carried across the epithelium by pIgR through transcytosis. Without that receptor, dimeric IgA made in the lamina propria could not reach the lumen at all.

"An injected vaccine gives the same protection as a natural mucosal infection." Not at the mucosa. Injection raises systemic IgG well but engages mucosal inductive sites poorly, so it generates little sIgA. This is why mucosal (oral or intranasal) vaccines exist and why some injected vaccines protect against severe disease better than against infection at the surface.

"Secretory component is contamination or leftover junk." No. It is a functional piece of the pIgR left attached to sIgA after transport, and it protects the antibody from the proteases that are abundant at mucosal surfaces.

"IgA protease cleaves all IgA." No. Bacterial IgA proteases are specific for IgA1, whose hinge region is longer and more exposed. IgA2 has a shorter hinge and resists them, which is part of why IgA2 is relatively more common at mucosal surfaces than in serum. The secretory component (from pIgR) protects against general proteases; IgA protease is a targeted enzyme that some bacteria make specifically to defeat sIgA.

References

1. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Philadelphia: Elsevier; 2022.
2. Punt J, Stranford SA, Jones PP, Owen JA. Kuby Immunology. 8th ed. New York: W. H. Freeman; 2019.
3. Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. New York: Garland Science; 2016.
4. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol. 2013;5:20401. https://doi.org/10.3402/jom.v5i0.20401